This offering is a follow-up to the Tata Capital Healthcare Fund I which had raised INR 411 Cr ($70 Mn) in 2012
The second fund has also received help from the ‘Self Reliant India (SRI)’ Fund of the central government under the Ministry of MSMEs
Around 60% of the new fund raised will be focused on the theme of domestic healthcare and life sciences consumption
Tata Capital has announced a $126 Mn (INR 955 Cr) fundraise by a private equity arm for investing in healthcare and pharma sectors in India.
The Tata Capital Healthcare Fund II (TCHF II) achieved a final closure of its fund with investor commitments of $126 Mn, said a statement by Tata Capital Limited.
The second fund has received commitments from domestic and international financial and strategic institutions including some of the global pharma, medical equipment companies, development financial institutions and large European institutions, as per the statement.
The second fund has also received help from the ‘Self Reliant India (SRI)’ Fund of the Government of India under the Ministry of Micro, Small and Medium Enterprises (MSME).
“TCHF II will seek to achieve returns by principally taking equity positions in healthcare and life sciences related companies having significant business exposure to India,” said Visalakshi Chandramouli, managing partner, TCHF.
Around 60% of the new fund raised will be focused on the theme of domestic healthcare and life sciences consumption, while the rest 40% will be devoted to companies focused on healthcare and life sciences competency through delivering products or services to the world markets, Chandramouli elaborated.
The new fund has already made commitments to three companies in the areas of domestic pharma formulations – Linux Pharma; diagnostic services- Atulaya Healthcare and digital health – Deeptek Inc., and expects to announce its fourth investment shortly, said Vamesh Chovatia, partner, TCHF.
Recommended For You:
“TCHF II is seeking to invest across sub-sectors of pharmaceuticals, pharma and allied services, healthcare delivery, medical devices and equipment and digital health,” Chovatia said.
The fund has a pipeline of deals and is expected to continue its deal momentum in the coming months. The fund will typically look at committing $5-15 Mn per transaction and potentially a larger ticket size along with co-investment support from its limited partners, who have committed to investing in the fund, Chovatia said.
Meanwhile, Tata Capital Healthcare Fund II, an investment arm of Tata Capital, has invested in healthtech startup DeepTek along with GHV to further empower and scale the latter.
Tata Capital Healthcare Fund has made its first investment in the digital healthcare segment with this investment on March 7, 2022.
Indian Healthcare Market Size Expected to Grow
The healthcare market can grow 3x to INR 8.6 Tn ($133.44 Bn) by the end of 2022, as per a report by India Brand Equity Foundation (IBEF), a trust established by the Department of Commerce, Ministry of Commerce and Industry.
In FY21, gross direct premium income underwritten by health insurance companies grew 13.3% year-on-year to INR 58,572.46 Cr ($ 7.9 Bn). The health segment has a 29.5% share in the total gross written premiums earned in the country, it said.
Moreover, the e-health market size is estimated to reach $10.6 Bn by 2025.
Meanwhile, FDI inflows for the drugs and pharmaceuticals sector stood at $18.12 Bn between April 2000 and June 202, according to the data released by the Department for Promotion of Industry and Internal Trade (DPIIT).